PMID- 33676551
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230614
IS  - 1710-1484 (Print)
IS  - 1710-1492 (Electronic)
IS  - 1710-1484 (Linking)
VI  - 17
IP  - 1
DP  - 2021 Mar 6
TI  - MicroRNA-29 mediates anti-inflammatory effects and alleviation of allergic 
      responses and symptoms in mice with allergic rhinitis.
PG  - 24
LID - 10.1186/s13223-021-00527-4 [doi]
LID - 24
AB  - BACKGROUND: To investigate the role of microRNA-29 (miR-29) in mice with allergic 
      rhinitis (AR) and its underlying mechanism. METHODS: AR model was established in 
      BALB/c mice by intraperitoneal sensitization and intranasal challenge with 
      ovalbumin (OVA). miRNA expression was examined in the nasal mucosa tissues of 
      mice and patients with AR, and miRNA-29 was found to be downregulated. To unveil 
      the role of miRNA-29 in AR, it was overexpressed in the nasal mucosa of AR mice 
      by intranasal administration of miRNA-29 agomir. The symptoms of nasal rubbing 
      and sneezing were recorded and evaluated. miR-29 expression, OVA-specific 
      immunoglobulin E (IgE) concentration, pro-inflammatory cytokines levels, 
      eosinophils number, and cleaved caspase-3 and CD276 expression were examined in 
      nasal mucosa tissues and nasal lavage fluid (NALF) by qRT-PCR, ELISA, hematoxylin 
      and eosin staining, western blotting, or immunohistochemistry, respectively. 
      TUNEL assay was used to analyze nasal mucosa cells apoptosis. RESULTS: Decreased 
      expression of miR-29 was observed in AR, the symptoms of which were alleviated by 
      overexpressing miR-29. In addition, overexpression of miR-29 markedly reduced the 
      concentration of OVA-specific IgE, the levels of IL-4, IL-6, IL-10, and IFN-gamma, 
      the pathological alterations and eosinophils infiltration in the nasal mucosa. 
      Furthermore, restoration of miR-29 expression reduced nasal mucosa cell 
      apoptosis. Moreover, overexpression of miR-29 significantly attenuated CD276 mRNA 
      and protein levels in nasal mucosa cells. CONCLUSION: MiR-29 mediated 
      antiallergic effects in OVA-induced AR mice by decreasing inflammatory response, 
      probably through targeting CD276. MiRNA-29 may serve as a potential novel 
      therapeutic target for the treatment of AR.
FAU - Wang, Jia
AU  - Wang J
AD  - Department of Otolaryngology Head and Neck Surgery, Beijing Shijitan Hospital, 
      Capital Medical University, No. 10 Yangfangdian Railway Hospital Road, Haidian 
      District, Beijing, 100038, China.
FAU - Yin, Jinshu
AU  - Yin J
AD  - Department of Otolaryngology Head and Neck Surgery, Beijing Shijitan Hospital, 
      Capital Medical University, No. 10 Yangfangdian Railway Hospital Road, Haidian 
      District, Beijing, 100038, China. yinjs@bjsjth.cn.
FAU - Peng, Hong
AU  - Peng H
AD  - Department of Otolaryngology Head and Neck Surgery, Beijing Shijitan Hospital, 
      Capital Medical University, No. 10 Yangfangdian Railway Hospital Road, Haidian 
      District, Beijing, 100038, China.
FAU - Liu, Aizhu
AU  - Liu A
AD  - Department of Otolaryngology Head and Neck Surgery, Beijing Shijitan Hospital, 
      Capital Medical University, No. 10 Yangfangdian Railway Hospital Road, Haidian 
      District, Beijing, 100038, China.
LA  - eng
PT  - Journal Article
PT  - Retracted Publication
DEP - 20210306
PL  - England
TA  - Allergy Asthma Clin Immunol
JT  - Allergy, asthma, and clinical immunology : official journal of the Canadian 
      Society of Allergy and Clinical Immunology
JID - 101244313
RIN - Allergy Asthma Clin Immunol. 2023 Jun 14;19(1):53. PMID: 37316883
PMC - PMC7936503
OTO - NOTNLM
OT  - Allergic rhinitis
OT  - CD276
OT  - Cytokines
OT  - Nasal mucosa
OT  - miRNA-29
COIS- The authors declare that they have no competing interests.
EDAT- 2021/03/08 06:00
MHDA- 2021/03/08 06:01
PMCR- 2021/03/06
CRDT- 2021/03/07 20:24
PHST- 2020/10/19 00:00 [received]
PHST- 2021/02/11 00:00 [accepted]
PHST- 2021/03/07 20:24 [entrez]
PHST- 2021/03/08 06:00 [pubmed]
PHST- 2021/03/08 06:01 [medline]
PHST- 2021/03/06 00:00 [pmc-release]
AID - 10.1186/s13223-021-00527-4 [pii]
AID - 527 [pii]
AID - 10.1186/s13223-021-00527-4 [doi]
PST - epublish
SO  - Allergy Asthma Clin Immunol. 2021 Mar 6;17(1):24. doi: 
      10.1186/s13223-021-00527-4.